Ensysce Biosciences Announces 50% Enrollment Milestone in Pivotal Phase 3 Trial of PF614 Opioid Candidate for Severe Acute Pain

Ensysce Biosciences has enrolled 50% of subjects targeted for interim review in its pivotal Phase 3 clinical trial of PF614, a next-generation opioid candidate engineered to deliver potent pain relief with built-in abuse protection. Enrollment began in late December 2025 and is progressing rapidly across three U.S. clinical sites. The trial is designed to demonstrate PF614's ability to deliver consistent, clinically meaningful post-surgical pain relief using twice-daily dosing.